A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

Recruiting at 6 trial locations

Overseen By Vaios Hatzoglou, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Memorial Sloan Kettering Cancer Center

Disqualifiers: Hpv-related opc, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

600 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream. The purpose of this study is to find out whether using this blood test to test for HPV DNA will help detect HPV-related Oropharyngeal Cancer/OPC.

Who Is on the Research Team?

Nancy Lee, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Ages 45 and older

Self-reported history of four or more lifetime sexual partners

Self-reported history of one or more lifetime oral sexual partner

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

Up to 5 years

Testing

Participants undergo blood testing using NavDx® to detect circulating HPV DNA

Follow-up

Participants are monitored for safety and effectiveness after testing

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• NavDx

How Is the Trial Designed?

Group I: No previous history of diagnosed HPV-related head and neck cancer Experimental Treatment 1 Intervention

Participants have no previous history of diagnosed HPV-related head and neck cancer

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+